Two days earlier than expected, the FDA approved Merrimack Pharmaceuticals Inc.’s Onivyde (irinotecan liposome injection) in combination with fluorouracil (5-FU) and leucovorin (LV), for patients with advanced pancreatic cancer previously treated with gemcitabine, giving the company its first ever U.S. drug approval.